1887

Abstract

In the present study the effect of the indole alkaloid ibogaine on the lipolytic activity and adherence to epithelial cells of was investigated. The substance was administered intraperitoneally at a dose of 5 mg kg day in mice with disseminated and gastrointestinal infections. Ibogaine significantly decreased the rate of mortality and the number of c.f.u. recovered from the kidney, liver and spleen. Ibogaine interfered with the early stages of both disseminated and gastrointestinal infections but did not reduce the number of c.f.u. in the organs at the late phase of infections. The development of a specific immune response was not influenced by ibogaine, since the delayed-type hypersensitivity reaction to and the production of interferon (IFN)-γ were similar in control and ibogaine-treated mice. The combined use of amphotericin B plus ibogaine in the treatment of mice with gastrointestinal infection reduced organ colonization more strongly than each substance alone.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.45919-0
2005-07-01
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/jmm/54/7/JM540705.html?itemId=/content/journal/jmm/10.1099/jmm.0.45919-0&mimeType=html&fmt=ahah

References

  1. Andriole V. T. 1999; The 1998 Garrod lecture.Current and future antifungal therapy: new targets for antifungal agents. J Antimicrob Chemother 44:151–162 [CrossRef]
    [Google Scholar]
  2. Baumann M. H., Rothman R. B., Pablo J. P., Mash D. C. 2001a; In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats. J Pharmacol Exp Ther 297:531–539
    [Google Scholar]
  3. Baumann M. H., Pablo J., Ali S. F., Rothman R. B., Mash D. C. 2001b; Comparative neuropharmacology of ibogaine and its O-desmethyl metabolite, noribogaine. Alkaloids Chem Biol 56:79–113
    [Google Scholar]
  4. Bennett D. E., McCreary C. E., Coleman D. C. 1998; Genetic characterization of a phospholipase C gene from Candida albicans : presence of homologous sequences in Candida species other than Candida albicans . Microbiology 144:55–72 [CrossRef]
    [Google Scholar]
  5. Cox G. M., McDade H. C., Chen S. C. & 8 other authors; 2001; Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans . Mol Microbiol 39:166–175 [CrossRef]
    [Google Scholar]
  6. Fidel P. L. Jr 2004; History and new insights into host defense against vaginal candidiasis. Trends Microbiol 12:220–227 [CrossRef]
    [Google Scholar]
  7. Fidel P. L. Jr, Vazquez J. A., Sobel J. D. 1999; Candida glabrata : review of epidemiology, pathogenesis, and clinical disease with comparison to C.albicans . Clin Microbiol Rev 12:80–96
    [Google Scholar]
  8. Fu Y., Ibrahim A. S., Fonzi W., Zhou X., Ramos C. F., Ghannoum M. A. 1997; Cloning and characterization of a gene (LIP1) which encodes a lipase from the pathogenic yeast Candida albicans . Microbiology 143:331–340 [CrossRef]
    [Google Scholar]
  9. Ghannoum M. A. 2000; Potential role of phospholipases in virulence and fungal pathogenesis. Clin Microbiol Rev 13:122–143 [CrossRef]
    [Google Scholar]
  10. Glick S. D., Maisonneuve I. M., Szumlinski K. K. 2000; 18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action. Ann N Y Acad Sci 914:369–386
    [Google Scholar]
  11. Glick S. D., Maisonneuve I. M., Szumlinski K. K. 2001; Mechanisms of action of ibogaine: relevance to putative therapeutic effects and development of a safer iboga alkaloid congener. Alkaloids Chem Biol 56:39–53
    [Google Scholar]
  12. Hanel H., Kirsch R., Schmidts H. L., Kottmann H. 1995; New systematically active antimycotics from the beta-blocker category. Mycoses 38:251–264 [CrossRef]
    [Google Scholar]
  13. Hough L. B., Pearl S. M., Glick S. D. 1996; Tissue distribution of ibogaine after intraperitoneal and subcutaneous administration. Life Sci 58:PL119–PL122
    [Google Scholar]
  14. Hough L. B., Bagal A. A., Glick S. D. 2000; Pharmacokinetic characterization of the indole alkaloid ibogaine in rats. Methods Find Exp Clin Pharmacol 22:77–81 [CrossRef]
    [Google Scholar]
  15. House R. V., Thomas P. T., Bhargava H. N. 1995; Comparison of the hallucinogenic indole alkaloids ibogaine and harmaline for potential immunomodulatory activity. Pharmacology 51:56–65 [CrossRef]
    [Google Scholar]
  16. Hube B., Stehr F., Bossenz M., Mazur A., Kretschmar M., Schafer W. 2000; Secreted lipases of Candida albicans : cloning, characterisation and expression analysis of a new gene family with at least ten members. Arch Microbiol 174:362–374 [CrossRef]
    [Google Scholar]
  17. Hube B., Hess D., Baker C. A., Schaller M., Schafer W., Dolan J. W. 2001; The role and relevance of phospholipase D1 during growth and dimorphism of Candida albicans . Microbiology 147:879–889
    [Google Scholar]
  18. Kariba R. M., Houghton P. J., Yenesew A. 2002; Antimicrobial activities of a new schizozygane indoline alkaloid from Schizozygia coffaeoides and the revised structure of isoschizogaline. J Nat Prod 65:566–569 [CrossRef]
    [Google Scholar]
  19. Komshian S. V., Uwaydah A. K., Sobel J. D., Crane L. R. 1989; Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 11:379–390 [CrossRef]
    [Google Scholar]
  20. Leidich S. D., Ibrahim A. S., Fu Y. & 8 other authors; 1998; Cloning and disruption of caPLB1, a phospholipase B gene involved in the pathogenicity of Candida albicans . J Biol Chem 273:26078–26086 [CrossRef]
    [Google Scholar]
  21. Mash D. C., Staley J. K., Pablo J. P., Holohean A. M., Hackman J. C., Davidoff R. A. 1995; Properties of ibogaine and its principal metabolite (12-hydroxyibogamine) at the MK-801 binding site of the NMDA receptor complex. Neurosci Lett 192:53–56 [CrossRef]
    [Google Scholar]
  22. Mash D. C., Kovera C. A., Pablo J., Tyndale R. F., Ervin F. D., Williams I. C., Singleton E. G., Mayor M. 2000; Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Ann N Y Acad Sci 914:394–401
    [Google Scholar]
  23. Molinari H. H., Maisonneuve I. M., Glick S. D. 1996; Ibogaine neurotoxicity: a re-evaluation. Brain Res 737:255–262 [CrossRef]
    [Google Scholar]
  24. Mukherjee P. K., Seshan K. R., Leidich S. D., Chandra J., Cole G. T., Ghannoum M. A. 2001; Reintroduction of the PLB1 gene into Candida albicans restores virulence in vivo . Microbiology 147:2585–2597
    [Google Scholar]
  25. O'Garra A., Steinman L., Gijbels K. 1997; CD4+ T-cell subsets in autoimmunity. Curr Opin Immunol 9:872–883 [CrossRef]
    [Google Scholar]
  26. Pfaller M. A. 1996; Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin Infect Dis 22:S89–S94 [CrossRef]
    [Google Scholar]
  27. Portnoy D. A., Smith G. A., Goldfine H. 1994; Phospholipases C and the pathogenesis of Listeria . Braz J Med Biol Res 27:357–361
    [Google Scholar]
  28. Price M. F., Wilkinson I. D., Gentry L. O. 1982; Plate method for detection of phospholipase activity in Candida albicans . Sabouraudia 20:7–14 [CrossRef]
    [Google Scholar]
  29. Saffer L. D., Schwartzman J. D. 1991; A soluble phospholipase of Toxoplasma gondii associated with host cell penetration. J Protozool 38:454–460 [CrossRef]
    [Google Scholar]
  30. Shearer G. M. 1998; HIV-induced immunopathogenesis. Immunity 9:587–593 [CrossRef]
    [Google Scholar]
  31. Songer J. G. 1997; Bacterial phospholipases and their role in virulence. Trends Microbiol 5:156–161 [CrossRef]
    [Google Scholar]
  32. Sugiyama Y., Nakashima S., Mirbod F., Kanoh H., Kitajima Y., Ghannoum M. A., Nozawa Y. 1999; Molecular cloning of a second phospholipase B gene, caPLB2 from Candida albicans . Med Mycol 37:61–67
    [Google Scholar]
  33. Titball R. W. 1993; Bacterial phospholipases C. Microbiol Rev 57:347–366
    [Google Scholar]
  34. Tsuboi R., Komatsuzaki H., Ogawa H. 1996; Induction of an extracellular esterase from Candida albicans and some of its properties. Infect Immun 64:2936–2940
    [Google Scholar]
  35. Wenzel R. P. 1995; Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 20:1531–1534 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.45919-0
Loading
/content/journal/jmm/10.1099/jmm.0.45919-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error